Examiners Amendment

United States Patent and Trademark Office (USPTO)

Office Action (Official Letter) About Applicant’s Trademark Application

EXAMINER’S AMENDMENT

Issue date:  January 15, 2022

Application has been amended as shown below.  As agreed to by Eric R. Moran on January 14, 2022, the examining attorney has amended the application as shown below.  Please notify the examining attorney immediately of any objections.  TMEP §707.  Otherwise, no response is required.  Id.  In addition, applicant is advised that amendments to the goods and/or services are permitted only if they clarify or limit them; amendments that add to or broaden the scope of the goods and/or services are not permitted.  37 C.F.R. §2.71(a).

IDENTIFICATION

The identification of goods and/or services is amended to read as follows: 

005:  pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for use in oncology; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations for the treatment of lung cancer; pharmaceutical preparations for the treatment of non-small cell lung carcinoma; pharmaceutical preparations for the treatment of colorectal carcinoma; pharmaceutical preparations for the treatment of pancreatic cancer; [DELETED pharmaceuticals comprising small molecules]; pharmaceuticals comprising small molecules for the treatment of cancer; pharmaceuticals comprising small molecules for the treatment of infectious diseases; pharmaceuticals comprising small molecules for the treatment of lung cancer; pharmaceuticals comprising small molecules for the treatment of non-small cell lung carcinoma; pharmaceuticals comprising small molecules for the treatment of colorectal carcinoma; pharmaceuticals comprising small molecules for the treatment of pancreatic cancer; [DELETED pharmaceuticals comprising compounds]; pharmaceuticals comprising compounds for the treatment of cancer; [DELETED pharmaceuticals comprising inhibitors]; pharmaceuticals comprising inhibitors for the treatment of cancer; pharmaceuticals for the treatment of solid tumors; pharmaceuticals for the treatment of advanced solid tumors

042:  research and development of pharmaceuticals in the field of oncology; providing information in the field of scientific and medical research related to oncology; research and development of pharmaceuticals; providing information in the field of scientific and medical research related to pharmaceuticals  

See TMEP §§1402.01, 1402.01(e).

/Hsu, Fong/

Trademark Examining Attorney

fong.hsu@uspto.gov

Law Office 129

Office:  (571) 272-2001

Fax: (571) 273-2001

United States Patent and Trademark Office (USPTO)

USPTO OFFICIAL NOTICE

Office Action (Official Letter) has issued

on January 15, 2022 for

U.S. Trademark Application Serial No. 90603915

A USPTO examining attorney has reviewed your trademark application and issued an Office action.  You may be required to respond to this Office action.  Follow the steps below.

(1)  Read the Office action HERE.  This email is NOT the Office action.

(2)  Respond to the Office action, if a response is required.  Respond by the deadline using the Trademark Electronic Application System (TEAS).  Your response must be received by the USPTO on or before 11:59 p.m. Eastern Time of the last day of the response period.  Otherwise, your application will be abandoned.  See the Office action itself regarding how to respond.

(3)  Direct general questions about using USPTO electronic forms, the USPTO website, the application process, the status of your application, and whether there are outstanding deadlines to the Trademark Assistance Center (TAC).

After reading the Office action, address any question(s) regarding the specific content to the USPTO examining attorney identified in the Office action.

GENERAL GUIDANCE

·       Check the status of your application periodically in the Trademark Status & Document Retrieval (TSDR) database to avoid missing critical deadlines.

·       Update your correspondence email address to ensure you receive important USPTO notices about your application.

·       Beware of misleading notices sent by private companies about your application.  Private companies not associated with the USPTO may mail or email you trademark-related offers and notices – most of which require fees.  The USPTO will only email official USPTO correspondence from the domain “@uspto.gov.”

·       Hiring a U.S.-licensed attorney.  If you do not have an attorney and are not required to have one under the trademark rules, we encourage you to hire a U.S.-licensed attorney specializing in trademark law to help guide you through the registration process.  The USPTO examining attorney identified above is not your attorney and cannot give you legal advice, but rather works for and represents the USPTO in trademark matters.